Navigation Links
Lupus Foundation of America Statement on Results for Clinical Study,of CellCept Released by Aspreva Pharmaceutical Company

Statement by Sandra C. Raymond, President & CEO of the Lupus Foundation of America, Inc.

WASHINGTON, June 27, 2007 /PRNewswire-USNewswire/ -- The Lupus Foundation of America, Inc. and more than 1.5 million Americans with lupus have been awaiting the preliminary findings of the Phase III clinical trials for CellCept(R), a potential treatment for lupus kidney disease being tested by Aspreva Pharmaceutical Company. Development of new treatments for lupus patients is critical because many of the drugs currently used to treat the disease are toxic and can cause serious medical complications or side effects, sometimes worse than the disease itself.

Preliminary data from the 24-week induction phase show that CellCept achieved results that are equivalent to those achieved with intravenous Cyclophosphamide (IVC), a chemotherapy which has been used to treat patients with lupus kidney disease (lupus nephritis) since the 1970s. However, while IVC has been referred to as the "standard of care" for treatment of lupus nephritis it has never been approved by the FDA as a treatment for lupus.

In order to meet the primary endpoint, the FDA required Aspreva Pharmaceutical Company to show that CellCept was superior in efficacy to IVC. The LFA contends that this bar was unreasonably set too high by the FDA. Equal efficacy and less severe side effects would be a compelling rationale for approving a drug for this underserved disease, which would be welcomed by people with lupus and their physicians. Furthermore, if more agents could be developed with less toxicity, there would be improved opportunities for combination therapies in the treatment of nephritis.

An additional concern is that if CellCept induces 52% remission and IVC induces the same percentage of remission, it may be that each is covering a different subset of the population. Thus having the alternative treatments available might be an important overall improvement in care for lupus nephritis patients. In line with this, the LFA is eager to see some subset analysis, for example, an analysis of how CellCept performs in patients of African descent, since IVC is known to be less effective for this population.

The preliminary data from Aspreva suggest that overall incidence of side effects were the same for CellCept and IVC. This is expected when all major and minor side effects are counted equally. However, there is a large body of published literature with convincing evidence that CellCept is better tolerated, and, more importantly to patients and their doctors, is associated with fewer serious or life-threatening infections, and hospitalizations. IVC is also linked to a high incidence of infertility, which is not the case with CellCept. We eagerly await further data from this new trial on these kinds of side effects, which patients and doctors are most concerned about.

The results released today are only preliminary findings. The LFA looks forward to further analysis of the data and will report this information as soon as it becomes available.

About the LFA: The Lupus Foundation of America is the nation's leading nonprofit voluntary health organization dedicated to finding the causes and cure for lupus. The LFA and its nationwide network of nearly 300 chapters, branches and support groups operate programs of research, education, support and advocacy.

CONTACT: Duane Peters of Lupus Foundation of America, Inc.,+1-202-349-1145

Web site: http://www.lupus.org//

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Related medicine technology :

1. Aspreva and Roche Announce Preliminary Results for Phase III Study Evaluating CellCept in Lupus Nephritis
2. Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B Showed Significant Reductions in Disease Activity in Patients with Active Systemic Lupus Erythematosus
3. Cellerant Therapeutics Reversed Autoimmune Disease in Lupus Mice with Transplant of Purified Donor Blood Stem Cells
4. La Jolla Pharmaceutical Provides Update on Interim Antibody Results From Riquent Lupus Phase 3 Trial
5. La Jolla Pharmaceutical Announces Positive Interim Antibody Results From Riquent Lupus Phase 3 Trial
6. The International Myeloma Foundation Says Data Reported at a Global Medical Meeting in Greece Demonstrates Improved Survival for a Wide Range of Myeloma Patients
7. The Christopher and Dana Reeve Foundation Expresses Disappointment Over President Bushs Veto of the Stem Cell Research Enhancement Act
8. Hypertension Education Foundation Survey Results Announced At American Society For Hypertension Annual Meeting Suggests Improved Control Of High Blood Pressure, But Misconceptions Still Exist
9. The International Myeloma Foundation Reports Positive Shift In Treatment Paradigm For Patients
10. Research Supported by Samuel Waxman Cancer Research Foundation Discovers Mode of Action of Arsenic-Based Drugs in Destroying Cancer Cells
11. The International Myeloma Foundation Says New Clinical Trial Results Could Improve Survival While Reducing Side Effects For Many Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... 19, 2017 Incretin Mimetics/GLP-1 Agonists, SNDRIs, Lipase ... The global anti-obesity drugs market is expected to ... the forecast period and CAGR of 38.7% in the second half ... a CAGR of 32.8% from 2016 to 2027. The market is ... $24,063 million in 2027. ...
(Date:1/19/2017)... -- Accuray Incorporated (Nasdaq: ARAY ) announced ... set the bar for excellence in customer satisfaction. The ... rating among radiation treatment delivery systems in the U.S., ... Briefing™. The most recent ratings trend also shows Accuray ... for 11 of the past 12 quarters. ...
(Date:1/19/2017)... LONDON , January 19, 2017 ... Grothey ; European Oncology & Haematology, 2016;12(Suppl 2):3-8; ... ... http://photos.prnewswire.com/prnh/20151014/276718LOGO) Published recently in ... the peer-reviewed journal from touchONCOLOGY, an article by ...
Breaking Medicine Technology:
(Date:1/20/2017)... (PRWEB) , ... January 20, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The ... bible in homes across the world. Yisrayl says this generation is a time like no ... to turn to the Bible. , Yisrayl says he does not want to sound like ...
(Date:1/20/2017)... ... January 20, 2017 , ... Doctor C LLC, a company ... January ECRM trade show to continue the marketing and distribution of its product, The ... for providing 400 percent better absorption than traditional vitamin C supplements. At the trade ...
(Date:1/20/2017)... (PRWEB) , ... January 20, 2017 , ... Lice Troopers, ... lice cases in families with school-aged children since the holiday season. , “It ... holidays with their families, sharing hugs and taking photos, which is the head-to-head gateway ...
(Date:1/20/2017)... FL (PRWEB) , ... January 20, 2017 , ... International ... of nutritional and bodybuilding supplements, announced it attended the January ECRM trade show in ... bodybuilder and nutritional scientist who was determined to create a line of products that ...
(Date:1/20/2017)... California (PRWEB) , ... January 20, 2017 , ... "TransFlare ... to use inside of Final Cut Pro X," said Christina Austin - CEO of ... the RED Dragon. Utilizing the Dragon Sensor,TransFlare 4K Mystique lens flare and light leak ...
Breaking Medicine News(10 mins):